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The aim of this work was to synthesize cationic dendrimer with a thermoresponsive polymer
tail and complex the dendrimer with negatively charged apoferritin protein nanocage. These
kind of systems are developed, for example, for biomedical applications.
Spermine dendron with atom transfer radical polymerization initiator in focal point
was synthesized successfully. Thermoresponsive poly(di(ethylene glycol) methyl ether
methacrylate) was in situ polymerized to the dendron to form the thermoresponsive
dendrimer. All products were characterized with 1H NMR. Cloud point of the final product
was determined with DLS, and it was shown to be between 25 and 35 °C.
Complexation of dendrimer and apoferritin was observed with DLS, SAXS and TEM.
Complexation was not temperature dependent but complexes had slight thermoresponsive
characteristics. Size and zeta potential of the complexes were dendrimer concentration
dependent. In defined salt concentration apoferritin and dendrimer formed also crystallline
structures.
To improve thermoresponsive properties of the dendrimer and especially of the complexes,
further development should be done in the polymerization of the dendron since longer polymer
tail could improve thermoresponsiveness. Also other dendrimer generations, dendrimers and
protein cages could be tested to enhance electrostatic interactions between the protein cage
and the dendrimer.
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ATRP Atom transfer radical polymerization
BBIB α-Bromoisobutyryl bromide
BMDO 5,6-benzo-2-methylene-1,3-dioxepane
BOC tert-butyloxycarbonyl
CCMV Cowpea chlorotic mottle virus
CDCl3 Deutered chloroform
CPT Cloud point temperature
CRP Controlled radical polymerization
D2O Deuterium oxide
DCC N,N-Dicyclohexylcarbodiimide
DCM Dichloromethane
DCR Derived count rate
DEGMA Di(ethylene glycol) methyl ether methacrylate
Dh Hydrodynamic diameter
DLS Dynamic light scattering
DMF Dimethylformamide
DNA Deoxyribonucleic acid
DP Degree of polymerization
DTPA Diethylene triaminepentascetic acid
EMSA electrophoresis mobility shift assay
Et3N Triethylamine
HMTETA 1,1,4,7,10,10-Hexamethyltriethylenetetramine
HOBt Hydroxybenzotriazole
LCST Lower critical solution temperature
MeOH Methanol
MRI Magnetic resonance imaging
NMR Nuclear magnetic resonance
OEG Oligo ethylene glycol
OEGMA Oligo(ethylene glycol) methacrylate
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PAMAM Poly(amido amine) dendrimer
PDEGMA Poly(di(ethylene glycol) methyl ether methacrylate)
PEG Poly(ethylene glycol)
PMEO2MA Poly(di(ethylene glycol) methyl ether methacrylate)
PNIPAM Poly(N-isopropylacrylamide)
PPI Poly(propylenimine) dendrimer
RAFT Reversible addition-fragmentation chain transfer
RNA Ribonucleic acid
SFRP Stable free radical mediated polymerization
THF Tetrahydrofuran
TLC Thin layer chromatocraphy
Tris Tris(hydroxylmethyl) aminomethane
UCST Upper critical solution temperature
VOC Volatile organic compound
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Introduction
This master’s thesis is composed of literature and experimental part. Literature part
introduces dendrimers and nanocarriers which may be used in biomedicine, for example in
drug delivery. Also atom transfer radical polymerization (ATRP) and thermoresponsive
polymers are introduced since they have essential role in the experimental part of this
study.
First, dendrimers are introduced by presenting their synthesis, properties and applica-
tions. Application introduction is focused on biomedical applications but also other
ones are presented. Nanocarriers are discussed by explaining the main concept and
introducing some examples and applications. From protein cage nanocarriers ferritin,
which was used in the experimental part, is presented more thoroughly. ATRP is
introduced in general by presenting its mechanism, kinetics and aspects which effect
synthesis. Finally, thermoresponsive polymers and their characteristics are introduced.
Poly(di(ethylene glycol) methyl ether methacrylate) is discussed in more detail as it
was the polymer utilized in the synthesis introduced in the experimental part.
In the experimental part practical execution, results and motivation of the study are
introduced. In addition, successfulness and possible improvements are discussed.
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Literature part
1 Dendrimers
Dendrimers are branched treelike molecules with rather unique properties. They have
well defined structure, they are monodisperse and their properties are mainly defined
by the end groups. Dendrimers consist of core and defined number of wedges spreading
out of the core. These wedges, also known as dendrons, are branched and composed of
monomeric building blocks. Each new monomer in a branch forms a new layer, and
the layers are called generations. Internal cavities are formed between branches when
dendrimer generation is high enough. Shape of the dendrimer depends on the number
of generations. Larger ones (above fourth generation) are known to be globular, smaller
ones have more a disc-like shape. For a schematic structure of a dendrimer see figure 1.1
Figure 1: Schematic structure of a dendrimer.1
Dendrimer properties are somewhat generation dependent. Number of branching points
and end groups increases with every new generation when multifunctional monomer is
used. With increasing generations symmetrical and spherical shape is formed. Surface
density increases as well, gradually leading to internal cavity formation and finally to a
dense outer layer so that access to the internal cavities is blocked. In general, small
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generation dendrimers have more flexible branches and an open structure, whereas
higher generation dendrimers have more defined spherical structure. Dendrimers also
have unique intrinsic viscosity. It increases only up to fourth or fifth generation after
which it diminishes. Also in bulk generation dependent properties, like decrease in
specific volume, are observed. These two phenomena can be explained with change in
the shape when dendrimer grows.1,2,3
Dendrimers are most often synthesized in convergent or divergent manner. Both of
these synthesis pathways have their pros and cons. In both methods protected and
unprotected steps alternate in the synthesis and purification is based on separation by
size.1
In divergent method multifunctional core is used for generation-by-generation growth of
the dendrimer (figure 2). This can also be called an inside-out method since synthesis
starts from the core and layers are grown on top of each other. First generation is
synthesized to the core with monomers having one reactive site and normally more than
one protected unreactive site. After the first generation has been attached, protection of
the end groups is removed and surface groups become active. Now these end groups can
be reacted with new monomer. This process can be continued until desired generation
is reached. In this reaction method every step must be done perfectly if monodisperse
product is desired. This can be achieved with efficient reactions and excess of monomers.
Effective purification is also one key to monodisperse final product. High molecular
weight of the dendrimer compared to the other reagents eases up the purification since
purification methods based on separation by size can be used. Separation of fully and
partly functionalized dendrimers is more difficult because errors occur only in one or
few branches, and therefore molecular weights are not significantly different.1
Figure 2: Divergent growth of dendrimer, a = activation of surface groups, g = dendritic growth.1
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Convergent method is the other popular synthesis strategy for dendrimer production.
Convergent method is also called outside-in method since dendrons of the dendrimer
are first synthetized and then attached to the core to form the dendrimer (figure
3). Dendrons are usually synthetized with protected and unprotected steps like in
the divergent method. Major problem of this method is in the last step because
with large dendrons steric hindrance makes the full attachment difficult. Excess of
dendronds and usage of spacer in the core can help to overcome this problem. However,
convergent dendrimers are often restricted to small generations due to the steric crowding.
Purification is normally easy since molecular weight of the dendron is much smaller
than the dendrimers and therefore they are easy to separate. If errors occur in the
final step, they are significant because one whole wedge is missing. Therefore, partially
functionalized dendrimers and fully functionalized dendrimers are also moderately easy
to separate. In this method, attachment of different dendrons to the core is possible
contrary to the divergent method.1,4,3
Figure 3: Convergent method of dendrimer growth, a = activation of the core, a* = activation of
surface groups, g = dendritic growth.1
Combinations of convergent and divergent methods can also be used. For example,
divergent method can be used to grow a low generation dendrimer and with convergent
method dendrons can be added to this small dendrimer. In this method, steric hindrance
is smaller than in pure convergent method. So called double-exponential method can
also be utilized. In this method, small generation dendrons are first synthesized and
then separated to two fractions. Other fraction is activated in the peripheral chain
end and the other fraction in the core. These two fractions are combined to form the
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dendrons which are then reacted to the core. In this way, more than one generation is
gained in one step. Also hypermonomers with larger amount of functional groups may
be used to form dendrimers with high end group density in only few reaction steps.1
Cycles of protection and unprotection can be avoided by using two different kinds
of monomers which are reactive with each other but not with alike monomers. This
method is known as orthogonal method. Biggest advantage compared to divergent and
convergent methods is the smaller amout of reaction steps since next generation can be
added without deprotection of the previous generation.1
Dendrimers are among other things designed for biomedical applications like drug
delivery and imaging. This is due to the suitable and somewhat unique properties.
Some of these properties are for example uniformity and possibility to modify molecular
weight and surface functionality. In other words, dendrimers may be adjusted to suite
conditions of specific application. Possibility of modification gives an excellent chance
to control movement and release of drugs since size and functionality of the dendrimer
mainly defines interactions in the body.1,5
Branched structure has its benefits as well as it enables enhanced attachment of drugs
and imaging agents to the delivery vehicle leading to lower amounts of drug carriers
and better contrast in imaging. Branches also give multivalency to binding. This can
be exploited for example in receptor binding6 to get better targeting of therapeutics.
Multivalency has likewise enhanced DNA binding7 with cationic dendrimers.1,5
In addition to previously mentioned pros, degradation of the dendrimers can be adjusted.
This may be done so that after dendrimer has released its load it will be degraded and
removed from the body. This helps avoiding bioaccumulation. Degradation can also
be used to release the drug load. Degradation can occur via hydrolysis8, ultraviolet
irradiation9 or with the help of catalytic antibodies10. Non-toxic metabolites are desired
in biodegradation. Dendrimers can also be removed as such. Small size compared to
polymeric micelles and liposomes enables faster filtration in the kidneys and removal
via urine. However, one must keep in mind that too small size or unsuitable shape can
lower the circulation time to ineffective levels.1,5
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Biocompability is one of the most important factors if the dendrimers are used in
biomedicine. Unwanted responses, bioaccumulation and harmful degradation metabo-
lites can be avoided with careful study of dendrimers. In vitro studies have shown
that poly(amido amine) dendrimers (PAMAM) 11 with terminal amine groups show
concentration and generation dependent toxicity. Anionic PAMAMs i.e. half-generation
PAMAMs 12 were less toxic as is the case with dendrimers covered with poly(ethylene
glycol) (PEG).1,5
Drug delivery is one of the biomedical applications of dendrimers, and it includes two
main approaches. Firstly, passive encapsulation of pharmaceuticals can be performed.
This method was introduced for the first time by Jansen et al.13 in 1994. Encapsulation
is based on hydrophobic and ionic interactions between dendrimer and drug. Especially
for hydrophobic drugs attachment inside a dendrimer with hydrophilic outer layer
improves solubility and prevents premature degradation. Weaknesses of this method
are in the release since spesific stability of the complex and sustained release of the
drug is hard to obtain. Also concentration variation of the drug in the dendrimers and
storage of complexes cause difficulties. PAMAM and poly(propylenimine) dendrimers
(PPI) are the most studied dendrimers on this research area. Since PAMAM dendrimers
have amine groups in the interior and often on the outer layer, ionic interactions and
hydrogen bonding are generally exploited in the drug binding. Toxicity of cationic
PAMAM has been lowered with PEGylation, and it has also improved circulation
times and sustained release14. PPI dendrimers have been neutralized for example with
galactose units15 to develop transportation and targeting of malaria drugs to liver.1,16
In addition to encapsulation, covalent linkage of therapeutics can be implemented. This
method was introduced a bit later in 1999 by Malik et al.17. Also in this method
PAMAM dendrimers have been studied the most. Compared to certain passive en-
capsulation methods and administration of free drug, covalent attachment of drugs
enhances sustained release18 and increases cellular uptake19. PEG has been utilized for
similar purposes as in passive encapsulation. Covalent linkage overcomes problems of
encapsulation as in this method drug loads are constant and storage can be handled
with lyophilization. Stimuliresponsive materials20,16 can be used to adjust release. In
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this way, drugs may be released for example at certain pH corresponding to spe-
cific environment. Release can also rely degradation of the covalent bonds in the body.
Extended release may, for example, be based on hydrolysis of the bonds.1,21
Imaging is one of the biomedical applications which has dendrimers already in use.
Dendrimers are used in imaging of for example tissue and organs. This study area
is under constant development since even more efficient imaging agents are desired.
First magnetic resonance imaging (MRI) dendrimers were PAMAMs combined with
diethylenetriamine pentaacetic acid (DTPA) chelated with Gd3+. These complexes
had better chelation than DTPA-Gd3+ complexes, preferable circulation propeties and
enhanced intravascular contrast with lower gadolinium amounts. This discovery has
led to further development of dendrimers for imaging. In general, larger dendrimers
are better for vascular imaging and smaller ones are used for renal imaging. This is
due to different clearing routes as larger ones are cleared via liver and smaller ones via
kidneys. With some commercial large dendrimers metabolization of dendrimer in the
liver can lead to Gd3+ -mediated toxicity22. Liver accumulation can be prevented to
some extent with attachment of PEG units. Overall, dendrimers give better contrast
and higher local Gd concentrations in comparison to small-molecule chelators.1,5
Dendrimers have also been studied for transfection applications which are as well in
the area of biomedicine. Successful transfection of nucleotic acids like RNA and DNA
can be used to increased production of protein or in silencing of genes. Challenges in
this methodology lay in efficient delivery since free nucleotic acids are degraded in body
circulation. In addition, targeting of them into specific tissue is difficult. To overcome
these problems, cationic dendrimers can be used in packaging and shielding of nucleotic
acids. Formation of these complexes is mostly relying on ionic interactions between
phosphate groups of nucleotic acids and cationic groups of the dendrimers. Excess of
dendrimer leads to positive charge and further to colloidal stability and interactions
with cell reseptors 23. Complexes have been shown to be taken into the cell in greater
amounts and for longer times24. Intake occurred via endocytosis and it is at least in
certain systems generation dependent.1,23,25
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Dendrimers can also be used as drug themselves. They have been proven to be capable to
remove neurodegenerative disorder causing prion proteins from infected cells26. This was
observed to be concentration and time dependent, but at non-toxic levels of generation
four PAMAM dendrimer removal of prion proteins to undetectable levels occurred in
one week. Also anti-viral applications have been developed to prevent binding between
cells and viruses.5
In addition to biomedical applications, dendrimers have been developed, for example,
for bioremediation processes. PAMAM dendrimers modified with benzoylthiourea have
been shown to be able to selectively separate heavy metals from water in pH 927.
Recovery was done by lowering the pH and separation with ultrafiltration. Additionally,
competing ions did not disturb separation. PAMAM dendrimers without modification
are also capable to bind cations like Cu2+28. These dendrimers did have better binding
capacity than linear polymers but they were more dependent on the pH. Also in this case
lowering the pH and ultrafiltration was used to separate copper from the dendrimers.
Dendrimers have also been developed for different sensors. Two main categories are
chemical and biological sensors. Chemical sensors can be used in solutions, in solid state
and to modify electrodes. This type of technology could be used in detection of toxics
and other dangerous compounds or in any application where event can be converted
to signal. Signal giving part of the dendrimer can be in any part of the dendrimer. In
solution applications porphyrin is a good example of environment sensitive ligands. It
has been used to denote pH by measuring changes in fluorescense29 and in chiroptical
sensing of ligating molecules30. Ferrocene dendrimers31 are one example of dendrimers
suitable for electrochemical sensors. These dendrimers are particularly used to detect
anions32 but combining them with triazole rings enables also detection of cations33.
Dendrimers may also be used to modify surfaces. These applications can utilize for
example surface plasmon resonance, and they can be used at the interface of solutions
and vapors. Detection of volatile organic compounds (VOCs) has been studied with
quartz microbalance. It was observed that polyphenylene dendrimer coatings were
capable to detect VOCs reversibly and with short detection times. In biological sensors
basic idea is the same but use is different. Biological sensors can be used for DNA
microarrays, immunoassays and to detect diseased tissue by observing pH.34
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1.1 Spermine dendrimer
Spermine35 is one of the three polyamides synthetized in mammalian cells, and it is
known to be related to cellular metabolism. It has four amine groups which of two are
primary and other two are secondary (Figure 4). Spermine has a positive charge in
physiological conditions which enables interaction with oppositely charged substances,
like DNA and RNA, in body. Therefore, spermine likely has a role in gene regulation.
Spermine synthetase mailfunction is also known to relate to Snyder-Robinson syndrome
which includes mental-retardation and skeletal defects.
Figure 4: Spermine
Spermine has been used to make cationic dendrimers 7. Each spermine dendrimer tail
contains three amine groups36 (figure 5). Spermine dendrimers are hydrophilic and have
a positive charge due to the amine groups. Positive charge enables electrostatic binding
with oppositely charged molecules like DNA7,37 can lead to DNA condensation and
even further to altered transcription. Strength of the binding relies on the multivalent
interactions originating from the multiple amine groups of spermine and with further
generations binding is improved. This binding can also be utilized in binding with
negatively charged viruses like cowpea chlorotic mottle virus (CCMV)36.
Figure 5: First generation newkome-type spermine dendrimer
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Spermine dendrimers can be synthesized in a Newkome-type manner7,38,39. First, a focal
point is synthesized from tris(hydroxymethyl)aminomethane and tert-butyl acrylate
forming tert-butyl-trisamine. Amine group of the focal point is protected during dendron
synthesis. Protection can be done, for example, with bentzyloxycarbonyl. Secondly,
spermine tails are attached to the focal point. Attachment is done with carbodiimide-
hydroxybenzotriazole (DCC/HOBt) coupling chemistry. In this reaction, primary amine
of the spermine and carboxylic acid of the deprotected end of the focal point form
amides. Generation of spermine dendrimer may be increased with Newkome-type
branching. T-butyl protection of acid groups is removed with formic acid and second
generation of tert-butyl-trisamine is attached with DCC/HOBt coupling chemistry.
Synthesis also includes protection of two secondary and one primary amine of spermine
before spermine tails are attached. Protection is done with tert-butyloxycarbonyl (BOC)
protection groups. In the final step BOCs are removed with HCl in methanol. Also
protection of the focal point may be removed if further dendrimer growth is desired36.
2 Nanocarriers
Advancement in nanotechnology has brought great promises to area of medicine.
Nanocarriers and their applications have been developed to enhance drug packag-
ing, controlled release and improved targeting. Nanocarriers can be used for example
as imaging and contrast agents in gene therapy and in drug delivery. Nanocarriers
include a large variety of different molecules and biological building blocks. One defining
characteristic is the size in nanorange. One example of nanocarriers is dendrimers and
polymers which are synthetic nanocarriers. Viruses and bacteriophages, on the other
hand, are natural nanocarriers as nature have designed them for metal, mineral and
nucleic acid storage and delivery. In future, natural protein cages structures might
be used in delivery of therapeutics. Protein cages can be chemically and genetically
modified to optimize binding and carrying properties to fit biomedical application.40,41
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Polymers can form different self-assembly structures which can be used as nanocarriers.
In general, polymers used are amphiphilic bloc copolymers. Aqueous micelles are
one example of these kind of systems. Micelles used in biomedicine have two phases;
hydrophobic core inside and hydrophilic part forming the outer layer of the sphere.
Micelles are especially suitable for delivery of hydrophobic molecules which are repelled
in aqueous environment of human body. To form micelles a certain concentration,
critical micellar concentration, must be reached. This factor can lead to a situation
where premature release of drug can occur when micelles are diluted in the body.
Polymersomes are one type of polymeric nanocarriers. Polymersomes are composed
of amphiphilic polymers forming a bilayer shell. Inner part is hollow. They can be
used to carry hydrophobic substances in the bilayer, or hydrophilic substances in the
core. They are not repelled in the body as the outer layer is hydrophilic. Polymers
containing long chains form so called hyberthick hydrophobic compartment which
decreases permeability. Similar to polymersomes are liposomes which are lipid bilayer
vesicles. Liposomes are formed of double chain amphiphiles which may be synthetic or
natural. Liposomes are already in clinical use.20
Polymers can also be used without self-assembly structures. In this approach, solid poly-
mer forms nanoparticles which can be used as nanocarriers. Compared to self-assembly
structures, broader range of sizes makes the system advantageous. Also geometry is
more controllable. These kind of systems are generally based on biodegrability lead-
ing to release of cargo. Common example of these kind of polymers is copolymer of
poly(lactic acid) and poly(glycolic acid) which both are biodegrable. Drug release can
be adjusted by modifying ratio of the monomers. Polymers can also be utilized by using
hydrophilic networks, also known as nanogels, as carriers. Pros in this method, besides
wide range of size and shape, are large free space and easy modification. Attachment of
wanted therapeutics can be done on the network or they can be entrapped inside the
nanogel. Stimuliresponsivenesses can also be exploited to release drugs at certain point.
Especially pH responsive nanogels have been studied to adjust release in stomach and
small intestine. These systems have been used in many applications in biomedicine.20
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Dendrimers top polymers in monodispersity and therefore they also have more controlled
properties. Multivalency is also an advantage since binding of drugs and other substances
is better. As previously discussed substances can be bound covalently or non-covalently.
Also cavities of dendrimer can be utilized.20
Protein cages are biological nanocarriers found from plants and animals. Protein
cages are structures with hollow interior and diameter of 10 to 100 nm. They are
normally formed of subunits, and they have three different surfaces: interior and
exterior surface, and surface between subunits. For schematic presentation of different
surfaces see figure 6. In biomedicine applications all of these surfaces can be utilized.
Interior is mainly used for encapsulation, exterior is often used for functionalization and
surface between subunits defines self-assembly of the nanocage. Advantages of protein
cages compared to synthetic nanocarriers are unifomity of the structure and diverse
possibilities of modification.41,42
Figure 6: Schematic presentation of three surfaces of protein cages available for modification.41
In drug loading and release attachment of drugs can be done in three different ways.
Firstly, proteins of the nanocarrier can be genetically modified43. In this way, position
and amount of drug conjugation may be adjusted. In addition, hydrophilicity of
the inner cavity may be modified to enable encapsylation of different substances.
Secondly, chemical modifications can be done covalently or non-covalently44. In covalent
attachment release may rely on labile or on stable bonds. With labile bonds release
may occur when for example pH changes. Changes in pH in physiological environment
can be exploited so that in certain conditions bonds are decomposed and drug released.
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When bonding is stable in biological conditions, release is based on biodegradation
of the whole structure. Non-covalent bonding can be utilized especially when interior
cavity is filled with drug which has affinity for the interior. In these applications slow
non-triggered release is often observed. Thirdly, structural modification of protein cages
triggered by change in environment can be used41. In this case, loading and release can
be done by opening of pores of the protein cage or by disassembling the whole cage.45
Targeting of protein cages may be enhanced with chemical and genetic modifications.
One example of chemical modification is attachment of folic acid which is especially
uptaken by cancerous cells. This is due to increased level of folate receptors in the
cancer cells46. Reseptor-specificity can also be achieved by genetic modification of
protein sequences to mach specific cell types. Targeting peptides may also be bound to
the protein cage with genetic fusion47. Immuno systems capability to recognize protein
cages could also be benefited in delivering of immuno modulating drugs. Targeting is
important to overcome natural biodistribution. When distribution is minimized, smaller
amount of the therapeutic is needed and therapeutic effect is enhanced.40,45
Before clinical use toxicity and immunoresponces must be thoroughly examined. Be-
sides side-effects like inflammatory response, immunological response clears protein
nanocages like CCMV rapidly from the system. To overcome possible immunological
response protein cages have for example been covered with polyethylene glycol. Immune
reorganization was lowered and no changes in stability or structure were observed.40,45
Protein cages may also be conjugated with polymers and dendrimers to achieve improved
pharmacological properties. Conjugation can be done covalently or non-covalently.
Non-covalent interactions is also known as supramolecular interaction. For covalent
attachment surface functionalities, like amines and carboxylic acids, of the protein
provide a good platform. Bonds may be stable or degradable in biological conditions
depending on desired function. If reversibility of the bonding is desired, supramolecular
assemblies are more advantageous since they are based on non-covalent chemical bonds
and biological interactions. In both cases different synthesis pathways may be used.
Grafting-to strategy involves separate production of the substance which will be attached
to the protein cage. This method is useful when polymer or dendrimer synthesis is
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not possible in conditions suitable for the protein cage. Grafting-from method involves
synthesis of organic substances in the presence of the protein cage. This method is often
used when polymers are polymerized from initiator attached on protein. Polymerization
is often done with controlled polymerization techniques. Grafting through strategy
involves synthesis of organic substance with multiple protein attachment places. Protein
is added after synthesis is completed to form the conjugate. For schematic presentation
of these three synthesis pathways see figure 7.48
Figure 7: Three different methods for conjugation of protein cages with dendrimers and polymers.48
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2.1 Ferritin
Ferritin is a round hollow protein found in most living organisms. It carries iron in
ferrihydrite form (also phosphate may be included). Ferritin has an outer diameter of 12
nm, inner diameter of 6 to 8 nm (figure 8). All together 4 500 iron atoms can be inside
the core but often amount is smaller. Protein coat of ferritin is called apoferritin and it
has a mass of 450 000 Da. Apoferritin is formed of 24 shell protein subunits. Amino
acid sequence of subunits may vary but normally number of amino acids is around
177. Generally, ferritins have two types of subunits: heavy (H-type) and light (L-type).
Masses of these subunits are ca. 21 and 19 kDa respectively. Subunits of apoferritin
have hydrophilic and hydrophobic endings which form channels with contribution of
respectively three and four subunit ends. Iron ions Fe2+are transferred via hydrophilic
tree-fold channels which have six negative charges. Apoferritin may be isolated from
ferritin.49
Figure 8: Ribbon diagram of human heavy ferritin.50
Ferritin’s function in a living organism is to store and release iron. Storage, also known
as biomineralization, of iron is important since free iron is toxic as it can catalyze
formation of free radicals from reactive oxygen substances (chemical equation 1). Storage
is also important because iron is essential in many body functions. Storage of iron has
a complex reaction route but overall reaction can be seen from chemical equation 2.
In the biological conditions mineral phases of lepidocrocite (γ-FeO(OH)) or goethite
(α-FeO(OH)) are formed. For these kind of formation see chemical equation 3 for
simplified reaction.49,50,51
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Fe2+ + H2O2 Fe3+ + OH– + HO• {1}
2Fe2+ + 2O + (H2O)x+3 Fe2O3(H2O)x + H+ + H2O2 {2}
4Fe2+ + O2 + 6H2O 4Fe(O)(OH) + H+ {3}
Ferritin subunits are responsible for biomineralization. Subunits may differ depending
on cell type, physiological state of the cell and function of the ferritin. Subunits have
different capabilities to convert Fe2+ to Fe3+ as only H-type subunits have ferroxidase. L-
type subunits, on the other hand, have more effect on the microenvironment. Therefore,
structure of the protein coat defines for example iron deposition and release rate.
Differences between prokaryotic, eukaryotic, and archaeal ferritins are known to exist
but overall structure is highly similar.49,50,51
Ferritin has isoelectric point between 4.5 and 5.5 which means that in neutral and basic
environment ferritin has a net negative charge52. Correspondingly, below isoelectric
point ferritin has net positive charge. Charged ferritins attract oppositely charged
particles and this leads to aggregation if attraction is high enough. Aggregation is
dependent on strength of the electrostatic interactions. In general, force between two
spherical particles with electric charge may be described equation 1, where z is the
particle’s charge, e is the elementary charge, 0 is vacuum permittivity, r is the relative
permittivity of the media and r is the distance between charged particles.
Fi,j =
zizje2
4pi0rr
(1)
Ionic strength of the solvent media affects Coulombic interactions between particles.
This may be described with Debye screening length which is the distance within mobile
charge carriers screen charge of particle they are surrounding. This may be described
with equation 2 where 0 is vacuum permittivity, r is the relative permittivity of the
media, kB is the Boltzmann constant, T is the absolute temperature, e is the elementary
charge, and ci and zi are the number densities and valencies of the electrolyte ions.
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κ−1 =
√
0rkBT
e2Σiciz2i
(2)
Ferritin has many applications due its useful properties53. As other nanocages, also
ferritin can be exploited as a nanocarrier. Its inner cavity can be used as a storage
place for therapeutics or imaging agents and its outer layer may be modified to enhance
targeting. Moreover, magnetoferritin has superparamagnetic core which may be utilized
in magnetic resonance imaging. Because ferritin has a low relaxitivity it must be
enhanced before it reaches levels needed. This can be done with controlled aggregation54,
mineralization with superparamagnetic iron oxide particles55, additional compounds56,
or with addition of enhanced MRI agents57. Mineralization of other ions58 like Mn2+
and Co2+ have also been reported. Since interior of ferritin is sequestered from the
outer environment, ferritin’s inner cavity could be used also as a reaction vessel for
catalytic reactions. For example, platinum (Pt0) has been synthesized inside apoferritin
and further used to catalyze hydrogenation of olefins59. In addition, protein cages could
be used in electronic devices. Especially, ability to control shape and size and therefore
magnetic properties makes ferritin attractive for further development of electronic
applications.50,60
3 Atom Transfer Radical Polymerization
In traditional radical chain polymerization products suffer from polydispersity. This is
due to chain transfer and bimolecular termination leading to short lifetimes of prop-
agating chains. Controlled radical polymerization (CRP) techniques may be used
to overcome these problems and to get well-defined polymers with low polydisper-
sity. Atom transfer radical polymerization (ATRP) is considered to be one of the
CRP techniques due to low amount of termination reactions. In ATRP bimolecular
termination has been minimized by forming dormant propagating species which are
inactive besides the short moments of propagation.Other CPR techiques are reversible
addition-fragmentation chain polymerization (RAFT) and stable free radical mediated
polymerization (SFRP).61,62
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In ATRP organic halide (R-X) is used as an initiator and it is activated with help
of transition metal compound (Mtz). This reversible redox reaction includes also a
ligand (L) which complexes with the transition metal compound (MtzL) and makes
it soluble into organic solvents. Ligand and transition metal complexes can together
be thought as a catalyst. During initiator activation halide (X) is withdrawn from the
initiator and passed to the transition metal complex (X-Mt z+1L) which is transferred
to higher oxidation state. Radical (R•) formed in this reaction is capable to react with
a monomer and can start the propagation. Deactivation of propagation occurs when
halide is returned from the transition metal complex to the radical. Hence, transfer
of the radical reduces termination by lowering active time of the propagating radicals.
Initiator is also called activator and oxidized metal complex deactivator. For summary
of the reactions occurring see chemical reactions 4.61,62
Mtz Ln + R X
kact
kdeact X Mt
z+1 Ln + R•
X Mtz+1 Ln + R• M X Mtz+1 Ln + RM•n {4}
RMnX + Mtz Ln + M
kp X Mtz+1 Ln + RM•n
Oxidation of transition metal complex takes place with a rate constant of activation kact
and opposite event respectively with a rate constant of deactivation kdeact. Normally
kact is smaller than kdeact since termination is wanted to be minimal. Equilibrium
constant Katrp is defined by the ratio of kact and kdeact (equation 3). Small Katrp leads
to slow propagation or no propagation at all. Too large Katrp will lead to large amount
of radicals, and therefore to increased termination leading to polydisperse product.
During active state polymerization occurs with a rate constant of propagation kp. Also
termination exists since polymerization is nevertheless a radical process, and it has a rate
constant kt. In a successful ATRP reaction termination is in minor part. Termination
of the polymerization can be minimized by adding deactivator in the beginning of the
reaction. This is useful especially when deactivator concentration increases slowly in
the start of the polymerization. Deactivator addition lowers radical termination and
leads to smaller polydispersity.61,62,63
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KATRP =
kact
kdeact
(3)
ATRP can be performed in bulk, solution, suspension and emulsion. Different solvents
can be utilized and temperature range is also broad. Different monomers, initiators
and transition metal complexes and their combinations give different rates of polymer-
ization.62
Equilibrium constant of the polymerization can be adjusted with many factors. It
mainly depends on the properties of the organic halide and the transition metal complex.
Homolytical cleavage of halogen from the organic halide is important for the radical
formation in the activation. Rapid homolysis ensures even growth of the chains and
low molecular weight distribution in final product. As it comes to the transition metal
complexes, reduction and oxidation of metal plays a key role. In addition to the
redox properties, metal catalyst has also other requirements because it has multiple
interactions during the reaction. First of all, transition metal has to have two oxidation
states and affinity for halogen because it needs to withdraw the halogen and be oxidized
simultaneously. Secondly, metal catalyst must have an expandable coordination sphere
for the withdrawn halogen. Finally, bonding strength of the transition metal with the
ligand and with the halogen must be sufficient. This is because metal catalyst should
stay soluble and be capable to keep the halogen to let the polymer propagate. Altogether,
equilibrium constant mainly depends on witch halogen is used in the initiator and on
the affinity of the catalyst for halide anion in question. Factors affecting equilibrium
constant are concluded in equation 4 where KBH describes homolytical cleavage of the
initiator, KEA stands for electron affinity of the halide i.e. reduction of the halide,
KHalido describes halidophilicity of the metal complex i.e. affinity of the halide to the
metal complex, KET is for electron transfer i.e. oxidation of the metal complex.61,62
KATRP =
KBHKEAKHalido
KET
(4)
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Reaction between halide and transition metal compound can be affected for example
with the choice of solvent and ligand61. Transition metal and ligand should form a
strong complex since solubility and redox potential of the metal catalyst dependent on
it. Ligand has a big effect on both kact 64 and kdeact 65 but also solvent63 has a significant
impact on them. Solvent effect can be predicted when redox potential of the catalyst
and relative values of electron affinity of the halides are known. For example, for
nitrogen based ligands activity generally increases with number of coordinating sites,
amount of linking C-atoms and with cyclic and bridged systems.
ATRP can be used for numerous monomers like acrylates, meta-acrylates, acrylamides
and 1-3-dienes. Equilibrium constants are unique to each monomer even though
otherwise same conditions are used.61
Also initiators can be chosen from a large selection of organic halides. Bromides are
known to react faster than chlorides, and they both are known to give a good control
over molecular weight. Iodides, on the other hand, react the fastest but tend to cause
side reaction. Fluorides in turn are inactive due to strength of the C-F bond. Most
important features of the initiator are fast and quantitative initiation and capability
of the halide to move from initiator to the transition metal compound. Reactivity of
the initiator should in optimum case be chosen according to the reactivity of chosen
monomer.61,62
Molecular mass of the polymer can be adjusted by changing initial concentration ratio of
monomer and initiator. By increasing amount of the monomer or by decreasing amount
of the initiator longer chains are obtained. Naturally, molecular mass depends also on
conversion as polymerization can be stopped before all monomer is consumed. In this
way also secondary termination is reduced. Degree of polymerization (DP) is defined
with equation 5 where M and I stands for initial monomer and initiator concentration
and conversion is ratio of reacted amount of monomer to total amount of monomer.61,62
DP = [M]0[I]0
∗ conversion (5)
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Structure of polymer can be changed by using different initiators with varying amount of
halides and diverse structures. This provides numerous possibilities, and polymers can
be anything from linear to star-like. Star polymers are obtained when multifunctional
initiator is used. Graft copolymers are produced when monomers with halogen containing
side groups are used. Polymeric initiators with multiple initiators produce bruch
polymers. Also end-groups can be varied by choosing initiators with different organic
parts. This might shorten synthesis pathways if desired end-group can be gained straight
from the initiator. One of the ends is always halide due to the propagation method,
but this can also be seen as an opportunity because halides are easily modified.61,62
ATRP can also be used to polymerize copolymers with different architectures. As in
radical polymerization, random, block and gradient copolymers can be made. Blocks are
achieved with two possible methods. Firstly, in one-pot sequential method monomer A
is first polymerized and monomer B is added after most of the A has reacted. Secondly,
in isolated macroinitiator method a polymer is used as a initiator. In both methods, a
halogen end group is required. Therefore, conversion of the first polymer should not
reach 100 % since secondary termination increases with decreasing monomer amount
leading to polymers with no halogen end group. One-pot method has its disadvantages
since monomer A causes contamination to the second block. With macroinitiator pure
blocks are achieved. Higher amount of blocks can be achieved with both methods. In
addition, difunctional initiator and coupling of chains can be used to gain copolymers
with multiple blocks.61,62
Usage of monomers from the same class, for example two acrylates, improves possibility
to gain a successful block copolymer via one-pot and macroinitiator method. Poly-
merization of monomers from different class should be done in a way where monomer
forming a macroinitiator with higher equilibrium constant is polymerized first.61,62
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4 Thermoresponsive polymers
Thermoresponsive polymers is one class of stimuliresponsive polymers, also known as
smart polymers. As the name, stimuliresonsive polymers, suggests these polymers
can undergo a change in their properties when certain stimuli is applied. These
polymers can be found in many geometries and sizes, anything from single molecules in
solution to polymer brushes. Stimulus applied may be chemical like pH, physical like
temperature, or biomedical like enzyme substrate. A physical stimulus affects molecular
interactions leading to phase transition. Stimuliresponsive polymers can be utilized in
many biotechnology and biomedical applications like in drug release and imaging. In
biochemical applications response to stimuli is preferably occurring in water solutions
since human body is to a great extent water.66,67
Thermoresponsive polymers can undergo a change in their conformation when tempera-
ture changes. Normally, this is observed in water solutions when change in solubility
and hydrophilicity occurs upon heating. Backbone of the polymer is often nonpolar and
therefore hydrophobic. Water solubility of the polymer rises generally from hydrophilic-
ity of the side chains. Water molecules bind to the polar groups of the polymer via
hydrogen bonding making the polymer water soluble. Hydrophobicity increases when
temperature is increased, and water molecules bound to the polymer are released to
the bulk. Simultaneously intra- and intermolecular bonding of the polymers increase.
Temperature where this occurs is known as lower critical solution temperature (LCST)
and cloud point temperature (TCP) or critical temperature (TCr). Cloud point refers to
temperature where clouding of the solution is observed. LCST refers to the temperature
below which polymer is soluble into the solvent and above it polymer becomes insoluble.
In other words, polymer undergoes a coil-to-globule transition. For a schematic picture
of the transition see figure 9.66,68
LCST is dependent on many factors like concentration, pressure, molar mass and
presence of electrolyte66,68. For example, for poly(N-isopropylacrylamide) (PNIPAM)
cloud point first increased with increasing pressure and after certain point cloud point
started to decrease69. Similar behavior has shown also for poly(N-vinylisobutyramide)
(PNVIBA)70. Only difference was that PNVIBA had the turning point at lower pressure
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and it was slightly sharper. Also electrolyte has been shown to have effect on LCST of
PNIPAM71. Different salts have different effects but generally LCST decreases with
increasing salt concentration. Some salts like NaSCN increases the LCST at some
salt concentrations but effect is much smaller than with LCST-decreasing salts like
Na2SO4. Molar mass dependence has been shown at least for 2-n-propyl-2-oxazoline
and its copolymers with 2-ethyl-2-oxazoline72. Increase in degree of polymerization
for the homopolymer decreased the cloud point. Change was most prominent in lower
molar masses. LCST of copolymers decreased with increasing chain length and with
2-n-propyl-2-oxazoline amount.
Figure 9: Coil-to-globule transition of thermoresponsive polymer.
Coil-to-globule transition can also occur vice versa and then polymer is said to have an
upper critical solution temperature (UCST). This means that polymer becomes soluble
when mixture is heated above certain temperature.66,68
Coil-to-globule change of thermoresponsive polymer can be discussed also by the means
of thermodynamics. In soluble state of the polymer Gibbs energy (∆G) is smaller
than zero and therefore favorable for the system i.e. for the hydrogen bonding between
polymer and solvent. When temperature is changed and polymer becomes insoluble
enthalpy part becomes bigger than entropic part and Gibbs energy changes to positive.67
One of the well-known thermoresponsive polymers is PNIPAM. It has been widely
studied since it has a LCST (~32 °C) near body temperature making it an interesting
choice for biomedical applications. On top of the suitable LCST, PNIPAM has a low
dependence on concentration and pH. A good alternative for PNIPAM is polymers with
short oligo ethylene glycol (OEG) chains as they have also a LCST. These polymers are
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usually composed of hydrophobic backbone and hydrophilic OEG side chains. LCST of
these polymers can be modified by copolymerization and by changing length of the side
chain i.e. adjusting hydrophilicity. In general, LCST is higher with increasing amount
of OEG units and with hydroxyl group in the end of the side chain. These both factors
increase hydrophilicity, and therefore also LCST increases. Copolymerization of for
example DEGMA and oligo(ethylene glycol) methacrylate (OEGMA) enables LCST
range between 28 °C and 90 °C73. Also molar mass, concentration and presence of salt
influences LCST. Polymerizations are mainly done with acrylates and methacrylates,
but also other monomers like styrenic monomers can be utilized.74,75,76
Oligoethylene glycol units are biocompatible as PEG polymers are but polymerization
technique is known to affect cytotoxicity of final products. In RAFT polymerization
chain transfer agent has impact on the toxicity. In ATRP purification should be done
preferably with dialyzes, not with precipitation, to get rid of toxic metals and monomers
used in the polymerization.75,77
Also dendrimers with oligoethylene glycols have been reported. These dendrimers have
a LCST ranging from 28 to 36 °C. LCST increases with amount of oligoethylene glycols.
Concentration of dendrimer had only a minimal effect on the LCST. Dendrimers were
found to be cytotoxic against human breast cancer cell line and the highest cytotoxicity
was with dendrimer with low hydrophilicity and large amount of end groups of ethoxy.78
4.1 Poly(di(ethylene glycol)methyl ether methacrylate)
Di(ethylene glycol)methyl ether methacrylate is methacrylic monomer with molecular
weight of 188.22 g/mol. It has a methacrylate group with double bond and ester group.
Besides that it has two ethylene glycol groups. DEGMA is polymerized by breaking
the double bond so that new carbon-carbon-bond is formed between two monomers.
From figure 10 structure of one repeating unit can be seen.76
Carbon backbone of the polymer is not water soluble but ethylene groups of the
repeating units make the polymer soluble below certain temperature. PDEGMA (aka.
PMEO2MA) has a LCST around 26 °C66. As earlier discussed, LCST can be modified
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Figure 10: PDEGMA
with copolymerization. For example, copolymerization with OEGMA enables LCST
range between 28 °C and 90 °C73. In addition, LCST is known to be concentration
dependent79 as it decreases with increasing concentration and levels up after 1 wt-%
concentration. Also increase in molecular weight was show to increase cloud point.
Additionally, hydrodynamic diameter of PDEGMA has been studied with DLS80. These
studies showed that large aggregates are formed around the LCST in 0.3 wt-% water
solutions, and the aggregates decrease in size with further heating.76
Properties of PDEGMA may be further improved by enhancing biodegrability. Biode-
grability of polymers with OEG side chains can be improved with copolymerization This
may be done using for example disulfides or esters as additional linkages. Latter option
has been used to make copolymer of DEGMA, OEGMA and 5,6-benzo-2-methylene-
1,3-dioxepane (BMDO)81. BMDO was used to gain biodegrability and different ratios
of DEGMA and OEGMA were used to gain different LCSTs. This polymer with
different ratios of the monomers was hydrolytically degradable as thermoresponsivity
and biocompatibility remained approximately the same.76
DEGMA monomers can be synthetized from di(ethylene glycol) metyl ether and acryloyl
chloride with the help of triethylamine in DCM under nitrogen atmosphere79.
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Experimental part
5 Intoduction
In biomedicine different kinds of system have been developed for enhanced drug delivery
and imaging. One example is protein cages which can be used for encapsulation and
delivery of therapeutics 45. Dendrimers can also be used in similar way to carry drugs
and imaging agents 20. Combinations of protein cages and dendrimers give even more
variability to the system. In this Master’s thesis, complexation of anionic apoferritin
and cationic thermoresponsive dendrimers is studied to develop water soluble and
temperature-controlled self-assemblies based on non-covalent interaction. For structure
of the final product see figure 11.
Figure 11: Final product, PD-G1-Sp dendrimer, formed from spermine dendron and polymerized
DEGMA monomer.
In the experimental part, synthesis of spermine dendron and polymerization practice
are introduced. This part includes also information about chemicals used, purifica-
tion methods and characterization. Properties of the synthesized dendrimer and the
complexes are discussed in the results part. Properties are also compared to similar
systems obtained before by others. In conclusions successfulness of the whole project is
discussed to examine failures and development ideas.
Dendron was synthesized utilizing organic chemistry and purifcation included mainly
column chromatography. Di(ethylene glycol) methyl ether methacrylate was polymerized
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with atom transfer radical polymerization and purification included dialysis. Spermine
dendron including an ATRP initiator was first synthesized and then DEGMA was
polymerized in situ to the dendron.
Successfulness of the synthesis was observed with nuclear magnetic resonance (NMR).
Properties of dendrimer were studied with dynamic light scattering (DLS). Dendrimer
was also complexed with apoferritin and complexation was observed as a function of
temperature, concentration and salt concentration. These measurements were done
with DLS, transmission electron microscopy (TEM) and small-angle x-ray scattering
(SAXS).
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6 Materials
Di(ethylene glycol) methyl ether methacrylate monomer was purchased from Aldrich
and it was purified by eluting trough Al2O3 with methanol. Hydroxybenzotriazole
(HOBt), N,N-Dicyclohexylcarbodiimide (DCC), triethylamine (Et3N), piperidine, α-
Bromoisobutyryl bromide (BIBB), pyridine, Na2SO4, NaCl, 1,1,4,7,10,10-Hexamethyltri
ethylenetetramine (HMTETA), CuBr, tris(hydroxymethyl) aminomethane (Tris) and
HCl (32 %) were all purchaced from Aldrich and used without further purification. Silica
and ninhydrin were purchased from Fluka and used as received. Protein assay dye reagent
concentrate was purchased from Bio-Rad and it was diluted with deionized water (1:4).
Apoferritin was purchased from Molecular Links Rome and used without purification.
Fmoc-G1-acid and triBocSpermine were synthetized by co-workers according to a known
protocol7. Ninhydrin stain was prepared by dissolving 1,5 g ninhydrin in 100 ml of
n-butanol and 3,0 ml of acetic acid. Dichloromethane (DCM), tetrahydrofuran (THF),
dimethylformamide (DMF) and methanol (MeOH) were purchased from Aldrich.
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7 Synthesis
7.1 Fmoc-G1-triBocSp
Figure 12: Synthesis of Fmoc-G1-triBocSp (1)
Fmoc-G1-acid (200 mg, 0.426 mmol) was dissolved in 15 ml of THF. Hydroxybenzotria-
zole (339.61 mg, 2.51 mmol), N,N’-Dicyclohexylcarbodiimide (495.22 mg, 2.39 mmol)
and triethylamine (405.21 mg, 4.00 mmol) were added. TriBocSpermine (924.50 mg,
1.79 mmol) was dissolved to 20 ml of THF. Solutions were combined and stirred for 66 h
in room temperature. One hour before stopping the reaction ca. 15 mg of DDC, HOBt
and ET3N were added. THF was removed in elevated pressure. The crude product
was purified with column chromatography (Biobeads) eluting with DCM/MeOH (9:1).
Thin-layer chromatography (TLC) was performed to monitor separation. Spots were
visualized with ninhydrin stain. Oily colorless product was obtained (303 mg, yield
39.66 %).
1H-NMR (400MHz, CDCl3): δ (ppm) 1.33 to 1.50 (81H, (CH3)3C; 12H, NCH2CH2CH2
CH2N), 1.64 (12H, NCH2CH2CH2N), 2.41 (6H, OCH2CH2CO), 2.94 to 3.31 (36H,
CH2CH2CH2N), 3.53 to 3.81 (6H, OCH2CH2CO; 6H, CCH2O), 4.19 (1H, Fmoc-CH),
4.27 (2H, Fmoc-CHCH2), 7.30 (2H, aromatic Fmoc-H), 7.39 (2H, aromatic Fmoc-H),
7.62 (2H, aromatic Fmoc-H), 7.76 (2H, aromatic Fmoc-H).
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7.2 NH2-G1-triBocSp
Figure 13: Synthesis of NH2-G1-triBocSp (2)
Fmoc-G1-triBocSp (303.00 mg, 0.15 mmol) was dissolved in 7 ml of DMF. Piperidine
(1383.83 mg, 16.25 mmol) was added and solution was allowed to react in room
temperature for 45 h. DMF and piperidine were removed under elevated pressure.
Crude product was purified with column chromatography (Biobeads) eluting with
DCM/MeOH (9:1). Separation was followed with TLC and ninhydrin stain. Product
was a clear wax. (254 mg, yield 94.29 %).
1H-NMR (400MHz, CDCl3): δ (ppm) 1.33 to 1.50 (81H, (CH3)3C; 12H, NCH2CH2CH2
CH2N), 1.64 (12H, NCH2CH2CH2N), 2.41 (6H, OCH2CH2CO), 3.03 to 3.28 (36H,
CH2CH2CH2N), 3.44 to 3.90 (6H, OCH2CH2CO; 6H, CCH2O).
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7.3 Synthesis Init-G1-triBocSp
Figure 14: Synthesis of Init-G1-triBocSp (3)
NH2-G1-triBocSp (254.20 mg, 0.14 mmol) was dissolved anhydrous DCM (15 ml). α-
Bromoisobutyryl bromide (65.25 mg, 0.28 ml) and pyridine (26.94 mg, 0.34 mmol) were
added. Reaction mixture was stirred in room temperature for 45 h. Small amount of
both BIBB and pyridine were added hour before stopping the reaction. Crude product
was purified by extraction twice with brine (20 ml). Water phase was extracted twice
with DCM (20 ml). Organic phases were combined and dried with Na2SO4. The solids
were filtered out and DCM was evaporated. Final purification was done with column
chromatography (Biobeads, DCM/MeOH 9:1) and with silica column chromatography
(DCM/MeOH, 95:5). Yellow wax was obtained (74.4 mg, yield 28.25 %).
1H-NMR (400MHz, CDCl3): δ (ppm) 1.36 to 1.52 (81H, (CH3)3C; 12H, NCH2CH2CH2
CH2N), 1.65 (12H, NCH2CH2CH2N), 1.83 (6H, C(CH3)2), 2.46 (6H, OCH2CH2CO),
3.04 to 3.30 (36H, CH2CH2CH2N), 3.61 to 3.80 (6H, OCH2CH2CO; 6H, CCH2O).
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7.4 Syntesis of Poly(DEGMA)-G1-triBocSp
Figure 15: Synthesis of Poly(Degma)-G1-triBocSp (4)
First, a solution of HMTETA (3.67 mg/ml) and CuBr (1.5 mg/ml) in MEOH was
prepared under nitrogen atmosphere. HMTETA in MeOH and CuBr were separately
purged with nitrogen gas for 20 min. HMTETA was added to the CuBr with a two-ended
needle. Nitrogen atmosphere was used to remove all air. 1 ml of this solution was added
to a nitrogen purged flask. DEGMA (400 mg, 2.13 mmol) and init-G1-triBocSp (20.62
mg, 0.01 mmol) were as well purged with nitrogen for 15 min and then added to the
flask. Reaction mixture was stirred for 50 h at 50 °C. NMR samples were taken after
26 h (conversion 55 %) and 47 h (conversion 67 %). NMR samples were taken with
nitrogen purged needles to avoid air contamination. Reaction was stopped by opening
it to air and by removing it from oil bath. Copper was removed by filtrating solution
trough silica eluting with methanol. All colored copper compounds were absorbed
into the silica. Part of the methanol was removed with rotary evaporation and rest of
the solution was purified with dialysis (MWCO 2 000) against methanol and water.
Methanol was changed after 2 h. Methanol was changed to water after 21 h and water
was changed after 45 h. Insoluble part of the mixture was separated by centrifugation
and both phases were dried with lyophilization. Water insoluble part of the mixture
was product. Product was a light yellow solid. (5.0 mg)
1H-NMR (600MHz, DMSO): δ (ppm) 0.68 to 1.03 (45H, OCOCCH3), 1.30 to 1.42 (81H,
(CH3)3C; 12H, NCH2CH2CH2CH2N), 1.56 (12H, NCH2CH2CH2N), 1.68 to 1.91 (7H,
polymerbackboneCH2), 2.27 (6H, OCH2CH2CO), 3.04 to 3.16 (36H, CH2CH2CH2N),
3.19 to 3.30 (54H, O(CH3), 3.40 to 3.49 (36H, CH2OCH2CH2OCH3), 3.49 to 3.71 (64H,
CH2OCH2CH2OCH3; 6H, OCH2CH2CO; 6H, CCH2O), 3.92 to 4.15 (30H, COOCH2).
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7.5 Poly(DEGMA)-G1-Sp
Figure 16: Synthesis of Poly(Degma)-G1-Sp (5)
Removal of BOC protection groups of spermines was done by dissolving poly(DEGMA)-
G1-triBocSp (5.0 mg, 0.001 mmol) to 5 ml of methanol. 1.2 ml of 32 % HCl was
added and reaction was allowed to react overnight. Solvent was removed under elevated
pressure and final product was dried with lyophilization. Product was a light yellow
wax (3 mg, 74.11 % yield).
1H-NMR (400MHz, D2O): δ (ppm) 0.80 to 1.18 (21H, OCOCCH3), 1.75 (12H, NCH2
CH2CH2CH2N), 1.88 (12H, NCH2CH2CH2N), 2.06 (8H, polymerbackboneCH2), 2.52
(6H, OCH2CH2CO), 2.96 to 3.18 (36H, CH2CH2CH2N), 3.19 to 3.31 (7H, OCH3),
3.31 to 3.48 (38H, CH2OCH2CH2OCH3), 3.49 to 3.90 (80H, CH2OCH2CH2OCH3; 6H,
OCH2CH2CO; 6H, CCH2O), 4.07 to 4.30 (16H, COOCH2).
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8 Characterization
First, stock solutions of PD-G1-Sp 10 mg/ml and 1 mg/ml were prepared. These were
used to make all the samples for DLS, TEM and SAXS. All dilutions and samples were
made in deionized water or NaCl solution.
All synthesis products were analyzed with 1H NMR in suitable solvent to confirm that
reactions were successful. NMR was also used to determine degree of polymerization
and molar mass of final product PD-G1-Sp. NMR82 is based on different magnetic
resonance of nucleus depending on its surrounding. If the nucleus is shielded by
additional electrons, smaller frequency is needed to get it resonate. In NMR spectra
lower resonance frequency is seen as higher chemical shift. That’s why NMR may
be used in qualitative analysis of organic compounds. Intensities in the spectra are
proportional to the amount of nuclei giving the signal. This aspect may be used
particularly in quantitative analysis.
In NMR sample preparation for dendrons deuterated chloroform was used, for polymer-
ized dendron with protection of spermine deuterated dimethyl sulfoxide was used and
for final product deuterium oxide was used as NMR solvent. Spectra were calibrated
according to the solvent peak and all shifts are in ppm scale. Spectra were measured
with Bruker AVANCE 400 MHz and analyzed with SpinWorks3.
Dynamic light scattering was used to determine properties of PD-G1-Sp and its com-
plexes with apoferritin. DLS83 size measurements are based on light scattering of
particles. Sample is illuminated with a laser and intensity fluctuations are analyzed
to get information about Brownian motion of the particles in the sample. Brownian
motion on the other hand is dependent on particle size in a way where smaller particles
move faster than bigger ones. This is based on the Stockes-Einstain equation (equation
6) where D is the diffusion constant, kB is Boltzmann’s constant, T is the absolute
temperature, η is the viscosity and r is the particle radius. In the instrument a digital
correlator measures this fluctuation and based on it a correlation function is formed.
From this function z. average size, and further volume, size and number distributions,
may be determined. Also scattering intensity depends on particle size.
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D = kBT6piηr (6)
Zeta potential measurements were done to examine surface electric charge of the final
product, apoferritin and the complexes. Zeta potential84 measurements are based on
determination of electrophoretic mobility i.e. velocity of the particles in a electric
field. When this is known, zeta potential may be determined from the Henry equation
(equation 7) where z is zeta potential, EU is electrophoretic mobility,  is dielectric
constant, η is viscosity, f(Ka) is Henrys function.
EU =
2zf(ka)
3η (7)
DLS was used to measure cloud point of final product PD-G1-Sp. DLS was also used to
observe apoferritin size over a temperature range to confirm that no changes occurred.
Cloud point measurements were done by measuring twice at every second degree on
a chosen temperature range. Cloud point samples were equilibrated 30 seconds after
every heating. Reversibility and stability of final product and complexes were tested
by switching multiple times between two temperatures, 18 °C and 50 °C. After every
temperature switch three measurements were done after two minute equilibrium time.
Complexation of apoferritin with PD-G1-Sp was as well studied with DLS. Complexation
samples were measured twice after every titration addition and equilibrated at least for
2 minutes to ensure that possible complexes are formed. Complex size measurement
as a function of temperature was done as cloud point measurements for PD-G1-Sp.
All measurement included eleven ten second long runs. All DLS measurements were
repeated to confirm the results. DLS measurements were done with Zetasizer Nano
S and analyzed with Zetasizer software which calculates z. average sizes and zeta
potentials.
Small angle x-ray scattering was used to observe crystallinity of apoferritin and PD-G1-
Sp complexes at different electrolyte concentrations. SAXS 85 is based on the Bragg’s
law which proposes that incident x-ray produces Bragg’s reflections when reflections
from the different planes interfere constructively. For crystalline samples this occurs
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when waves are scattered from crystal planes separated by distance d. From equation 8
Bragg’s law, where n is integer, λ is wavelength, d is spacing between lattices, and sinθ
is the angle between the incident ray and the scattering planes, can be seen.
nλ = 2d sin θ (8)
Diffraction vector q may be calculated with the help of Bragg’s law from the following
equation:
q = 4pi
λ
sin θ (9)
From equations 10, 11 and 12 parameter g*, lattice parameter a for cubic phases, and
distance d between adjacent lattice planes in cubic phases can be calculated. In the
equations q is the measured SAXS reflection and h, k and l are the Miller incides.
q* = q√
h2 + k2 + l2
(10)
a = 2pi
√
h2 + k2 + l2
qhkl
(11)
d = a√
2
(12)
Samples were prepared in deionized water with 10 mM and 20 mM final NaCl concen-
tration. Samples were sealed with Kampton foil. Beam was produced with rotating
anode Bruker Microstar microfocus X-ray source (Cu Kα radiation, λ=1.54 Å) and
monochromated with Montel multilayer focusing monochromator (Incoatec). The X-ray
beam was further collimated by a set of four slits (JJ X-ray). Detection was done with
Hi-Star 2D area detector (Bruker).
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Transmission electron microscopy imaging was used to observe complexation of apofer-
ritin and PD-G1-Sp in different dendrimer concentrations and with electrolyte. TEM86
is based on electron beam transmitted through a thin sample. Electrons then interact
with the sample and information is collected from the transmitted beam which contrast
depends on sample properties. In this study, TEM data was collected to support DLS
data of complexation. TEM samples with 10 mM NaCl concentration was also prepared
to further investigate crystallinity of apoferritin and PD-G1-Sp complexes. Samples
were prepared in deionized water and negative staining with uranyl acetate was used.
FEI Tecnai 12 Bio Twin TEM was used in the imaging and ImageJ was used in the
image processing.
9 Results and discussion
9.1 NMR
1H NMR confirmed that all reactions were complete and that purification was sufficient
enough. For the final product length of the polymer tail was defined based on integration
of all peaks. In the PD-G1-triBocSp spectra integral calibration was done for the 1.30-
1.42 ppm peak (93 protons) and in the PD-G1-Sp spectra calibration was done for the
2.96-3.18 ppm peak (36 protons). In both cases amount of the repeating units of the
polymer was determined from the 3.92-4.15/4.07-4.30 ppm peak corresponding to two
protons of the first carbon after methacrylate group of the side chain. This integral
divided with two gives number of the repeating units. Based on this calculation PD-G1-
triBocSp has 15 repeating units and PD-G1-Sp has eight repeating units. Difference
between these two may be because of further purification of the product, degradation
of the polymer tail or due to poor choice of NMR solvent. Most probable cause is the
further purification.
Overall, polymer tail is short when compared to the initial amount of monomer. This
might be because of termination of the polymerization due contamination. Polymer-
ization conditions might also have been unsuitable or dendrimer might cause steric
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hindrance. According to the NMR samples taken during the polymerization conversation
is at least 67 %, and therefore degree of polymerization should be much higher (142 re-
peating units) than observed. This might be explained with additional initiator besides
the dendrimer initiator. Possible additional initiator could originate from the previous
synthesis step where α-bromoisobutyryl bromide is attached to the dendrimer. BIBB
can be used as ATRP initiator also as such. Therefore, monomer is likely consumed also
by other initiator leading to shorter polymer chain in the dendrimer. Better purification
or different synthesis route should be used to eliminate unintentional polymerization.
Long polymerization time would also refer to unsuitable polymerization conditions.
Therefore, polymerization parameters like solvent, temperature and ligand should be
optimized.
Molecular weight of the final product with eight repeating units from the PDEGMA
according to the 1H NMR is 2 502.98 g/mol.
9.2 DLS
To determine cloud point of the final product, PD-G1-Sp, samples with 50, 100 and
150 mg/l concentration was prepared. Different concentrations were used to see if
cloud point is concentration dependent. First measurement was done for 50 mg/l
solution between 5 °C and 80 °C to define suitable range for further measurements.
Other measurement for the same concentration was done between 5 and 59 °C. For
100 mg/l solution measurements were done ranging from 15 to 55 °C and from 5
to 61 °C. For 150 mg/l sample measurements were done twice between 5 °C and
59 °C. Z. average particle size (diameter in nm) i.e. hydrodynamic diameter Dh and
average derived count rate (DCR in kilo counts per second (kcps)) were calculated
for each temperature measured. Apoferritin sample (100 mg/l) was as well prepared.
Measurement for apoferritin was done ranging from 15 °C to 63 °C. From these results
at each temperature an average diameter was calculated for apoferritin. Calculation
was done based on the volume particle size distribution. Average diameter of apoferritin
was 11.11 nm and it remained approximately the same trough whole temperature range.
Size corresponds well with the theoretical diameter of 12 nm.
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Cloud point of the PD-G1-Sp was shown not to be concentration dependent in the
concentrations measured. For samples with concentration of 50, 100 and 150 mg/l
z. average size decreases with increasing temperature. For 50 mg/l sample (figure 17)
this decrease occurs around 25 °C, and it is rather sharp. Before transition variation
on size is somewhat big (between 200 and 300 nm) and afterwards it stabilizes around
160 nm. Samples with concentration of 100 mg/l (figure 17) have diameter between
400 and 700 nm before transition, and the z. average size levels between 200 and 250
after transition. Transition occurs after 35 °C and is not as sharp as in the smaller
concentration. For samples with concentration of 150 mg/l (figure 18) before transition
z. average size is between 300 and 600 nm and it starts to decrease around 30 °C.
Finally, size stabilizes to 220 nm. Transition is less sharp than in 50 mg/l samples.
Figure 17: Derived count rate and z. average size of PD-G1-Sp 50 mg/l (left) and 100 mg/l (right)
solution as a function of temperature.
In general, in higher concentrations z. average size is bigger throughout measurement
and decrease in size happens more slowly. However, 100 mg/l concentration has the
biggest particles at every temperature. For comparison of the z. average sizes in different
concentrations see figure 18.
Large z. average size already in the beginning of the measurement indicates that
dendrimers are associated at least to some extent and are not as individual particles.
In higher concentrations larger aggregates are formed. Fluctuation in the size before
transition might be because of assembly and disassembly of the dendrimer aggregates.
Decrease in the z. average size is most probably due to the coil-to-globule transition
of the dendrimer’s polymer tail. As the polymer is packed denser also dendrimer
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Figure 18: Derived count rate and z. average size of PD-G1-Sp 150 mg/l (left) and comparison of z.
average sizes of all concentrations measured (right) as a function of temperature.
aggregates become smaller. Standard deviation in z. average size results is bigger at
measurement points before transition, indicating more fluctuation in size also within
one temperature. After transition standard deviation is minimal. This is probably due
globular conformation of the polymer giving particles more stable and homogeneous
shape.
Change in the sample can also been seen from derived count rate. In samples with
50 mg/l (figure 17) DCR increases with increasing temperature and decreasing size.
DCR is approximately 700 kcps before change and it stabilizes at 7000 or 4000 depending
on the sample. Difference in this might originate from different cuvettes used. Class
cuvette, instead of plastic one, was used when higher DCR was observed. Different
cuvette was used because plastic cuvettes are not suitable in high temperatures which
were used in some samples with 50 mg/l concentration. For 100 mg/l samples (figure 17)
DCR increases as well with increasing temperature. DCR start from 1000 kcps and
steadily increases to 3500 kcps or over. Samples with concentration of 150 mg/l
(figure 18) have also increasing DCR starting from 2000 kcps and leveling to 9000 kcps
or over.
Decrease in size and opposite behavior in count rate indicates a change in the polymer
conformation rather than disassembly of aggregates. When temperature is increased a
coil-to-globule transition occurs and particle size decreases. In coil-to-globule transition
also refractive index of the polymer is likely to change leading to increase in the derived
count rate.
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Table 1: Z. average diameters and derived count rates (DCR) below and above cloud point for different
apoferritin concentrations.
apoferritin
(mg/l)
z. average diameter
below LCST (nm)
z. average diameter
above LCST (nm)
DCR below
LCST (kcps)
DCR above
LCST (kcps)
50 240 150 700 4000
100 460 250 1000 3500
150 350 220 2000 9000
Z. average size was studied also by switching temperature between 18 and 50 °C to
see how reversible the coil-to-globule transition is. These measurements were done for
samples with concentration of 100 and 150 mg/l (figure 19). For both samples transition
was reversible and size at both temperatures remained approximately the same even
after 20 switches. For 100 mg/l sample at 50 °C z. average size remained stable around
180 nm. At 18 °C more variation was observed but size remained mainly around 300
nm. For 150 mg/l sample at 50 °C z. average size was as well stable remaining at
180 nm diameter. At 18 °C more fluctuation occurred but size was somewhat stable
between 230 and 310 nm. This demonstrates that switching between temperatures
below and above cloud point may be done multiple times reversibly.
Figure 19: Temperature cycle for 150 mg/l (left) and 100 mg/l (right) PD-G1-Sp sample.
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Complexation of apoferritin and PD-G1-Sp was studied by titrating apoferritin solutions
with PD-G1-SP solution. Titration was done in two temperatures, 18 °C and 50 °C,
to see how temperature affects complexation. Formation of complexes and amount
of free apoferritin were observed with DLS. First, apoferritin solution with 750 µl
volume and 100 mg/l concentration was prepared. At each measurement step, 2 µl of
0.5 mg/ml PD-G1-Sp solution was added. After every addition, PD-G1-Sp concentration
in the sample increased by 1.3 mg/l. With some samples titration was continued with
1 mg/ml and 2.5 mg/ml solutions to see what is particle size in higher dendrimer
concentrations. Titration studies were also done with higher apoferritin concentration
to see if concentration has effect on complexation. Apoferritin solutions with 400 mg/l
concentration and 100 µl volume were prepared, and they were titrated with 0.5 mg/ml
PD-G1-Sp solution by adding 2 µl at each measurement point. After every addition
PD-G1-Sp concentration was increased with 10 mg/l. To define more detailed point
for complex formation same measurement was done by using 0.25 mg/ml PD-G1-Sp
solution. After every addition concentration of PD-G1-Sp increased with 5 mg/l.
Titration of 100 mg/l apoferritin samples indicated that temperature does not have a
significant impact on complexation. At 50 °C, 9.1 mg/l of PD-G1-Sp was enough to
complex all apoferritin. At 18 °C, 10.4 mg/l of PD-G1-Sp was needed for complexation.
Difference is negligible as at both temperatures roughly one tenth of the apoferritin
concentration was enough to tie up all apoferritin. All together 26 µl of PD-G1-SP
solution was added resulting PD-G1-Sp concentration of 16.9 mg/l. As free apoferritin
disappears and more PD-G1-Sp is added, bigger secondary complexes start to form. In
both temperatures, at the last titration point size of the complexes is around 2000 nm
in diameter. For comparison of volume-average sizes before and after titration see figure
20. From this graph can be seen that uniform secondary complexes are formed whereas
free apoferritin disappears. For volume percent of free apoferritin and hydrodynamic
diameter as a function of PD-G1-Sp concentration see figure 21. Further additions of
PD-G1-Sp indicated that Dh fluctuates between 2000 and 4000 nm.
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Figure 20: Volume-average size distribution of free apoferritin and apoferritin–PD-G1-Sp complexes
(left) and corresponding autocorrelation functions (right).
Figure 21: 100 mg/l apoferritin solution titrated with 0.5 mg/ml PD-G1-Sp solution. Upper picture
presents volume percent of free apoferritin in solution and lower graph presents hydrodynamic diameter
of particles in solution as a function of PD-G1-Sp concentration.
For 400 mg/l apoferritin solutions results were similar except that at 50 °C bigger
amount of PD-G1-Sp was needed compared to titration at 18 °C. At 18 °C, 40 mg/l
of PD-G1-Sp was sufficient to bind all free apoferritin, whereas at 50 °C, 50 mg/l was
needed (figure 22). Final concentration of PD-G1-Sp in the sample was 100 mg/l after
adding 20 µl of PD-G1-Sp solution. In these concentrations complexes formed are
larger than in smaller concentration, reaching 4000 nm diameter. For volume percent of
free apoferritin and hydrodynamic diameter as a function of PD-G1-Sp concentration
see figure 22. Titration with 0.25 mg/ml solution gave similar results where at 18 °C
45 mg/l was needed, and at 50 °C 50 mg/l of PD-G1-Sp was enough. This titration
was done only to the point where complexes are formed. Once again one tenth of
the apoferritin amount was needed to bind all free apoferritin and difference between
temperatures is small.
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Figure 22: 400 mg/l apoferritin solution titrated with 0.5 mg/ml PD-G1-Sp solution. Upper picture
presents volume percent of free apoferritin in solution and lower graph presents hydrodynamic diameter
of particles in solution as a function of PD-G1-Sp concentration.
When molar ratio of PD-G1-Sp to apoferritin at complex formation point is compared
(table 2), can be seen that at all apoferritin concentrations molar amount of the PD-
G1-Sp is larger than apoferritins. Moreover, at higher apoferritin concentration larger
amount of PD-G1 compared to apoferritin is needed for complexation.
Table 2: Molar ratio of PD-G1-Sp to apoferritin and PD-G1-Sp concentration at complex formation
point at different temperatures and apoferritin concentrations.
apoferritin (mg/l) PD-G1-Sp (mg/l) molar ratio temperature °C
100 9.1 16.38 50
100 10.4 18.72 18
400 45 20.45 18
400 50 22.5 50
Similar complexation behavior of ferritin has been seen also previously. For example,
magnetoferritin has been complexed with low generation dendrimers with spermine
tails87. In these studies analogous secondary complexes were formed as free magnetofer-
ritin simultaneously disappeared. Additionally, these complexes could be disassembled
with UV irradiation. Also other protein cages have been used to form complexes with op-
positely charged substances. CCMV is one of the extensively studied protein cages with
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negative surface charge. It has been complexed, for example, with janus-dendrimers36
and thermoresponsive polymers88 with formation of same kind of complexes as observed
in this study.
Size of the complexes as a function of temperature was observed by measuring hydrody-
namic diameter between 15 °C and 55 °C. These measurements were done for complexes
gained from titration measurements. For 400 mg/l ferritin sample, decrease in Dh and
derived count rate was observed with increasing temperature. For 100 mg/l ferritin
samples, similar decrease in size was observed. Derived count rate, on the other hand,
seemed to increase. Consistency in these measurements was difficult to observe in ether
sample as variation in both Dh and derived count rate between samples was observed.
Only common characteristic was decrease in size from 3000 nm to 1500 nm. For 100
mg/l samples, increase in the derived count rate indicates coil-to-globule transition
of the polymer tail as refractive index changes in the transition. Same behavior was
observed in samples with only PD-G1-Sp. In 400 mg/l samples, decrease of the derived
count rate refers more likely to disassembly of the complexes as normally small particles
scatter less light that bigger ones. This would also be in line with the decrease of the
hydrodynamic diameter. However, this is in contradiction with previous results where
count rate increased even though size gets smaller. Decrease of derived count rate could
possibly be explained with the large amount of apoferritin. Complexes might in these
concentration rather disassembly, when coil-to-globule transition occurs, than stick
together. This would then also overrule effect of the polymers coil-to-globule transition
where refractive index changes.
For systems containing nanoparticles coated with thermoresponsive polymer, heating
often makes the complex size to increase. This can, for example, be seen for gold
nanoparticles coated with PNIPAM89 where hydrodynamic radius of aggregates in-
creased from 83 nm to 114 nm upon heating. Also protein cages have been coated with
thermoresponsive polymers. Direct coating of a model protein, green fluorescent protein,
was done with copolymer of poly(methylacrylamide) and PNIPAM in two different
shapes90. In both cases aggregate size increased upon heating but aggregates with
linear shaped polymer were bigger compared to the Y-shaped ones. Also for CCMV
and thermoresponsive polymer increase in complex size is observed when system is
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heated88. Only partial complexation of CCMV and polymer is observed below cloud
point but when system is heated complete complex formation is observed in addition
with increased hydrodynamic diameter.
Stability of complexes was studied by cycling them between 18 and 50 °C and measuring
hydrodynamic diameter at these temperatures. Each measurement included 20 cycles.
No consistency with ether concentration was observed. This may be because of sedi-
mentation due to long measurement times and large size of the complexes. Complexes
might also need more time to stabilize their state after temperature change. With low
volumes water evaporation leading to drying of the sample was also observed. Further
studies could be done by optimizing measurement parameters.
In addition, zeta potential of apoferritin, PD-G1-Sp and different mixtures of previously
mentioned were measured. For apoferritin, zeta potential was negative, -21.70 mV, as
expected. For PD-G1-Sp, zeta potential was positive, 7.59 mV, which probably is due
to the spermine tails of the dendrimer. Complex solution with 100 mg/l apoferritin and
16.9 mg/l PD-G1-Sp has zeta potential of -10.15 mV. When PD-G1-Sp concentration
is increased to 54.7 mg/l, zeta potential is positive, 3.91 mV. When concentration
of the dendrimer is further increase to 130 mg/l and apoferritin concentration is 94
mg/l, zeta potential increases to 4.39 mV. Concentrations of the last measurement were
recalculated after titration because volume increased over 5 %. For diagram of zeta
potential dependence on PD-G1-Sp concentration see figure 23.
Figure 23: Change of zeta potential as a function of PD-G1-Sp concentration when inital apoferritin
concentration is 100 mg/l.
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Results from zeta potential measurements indicate that electric charge of the complexes
may be varied and negative charge of the ferritins screened. This enables modification of
the complexes to suite different purposes. Probably at some dendrimer concentrations
complexes are also neutral.
9.3 SAXS
SAXS samples were prepared by mixing 5.0 µl of 10 mg/ml apoferritin solution, 1.25 µl
of NaCl solution and 3.75 µl of 10 mg/ml PD-G1-Sp solution in corresponding order.
For 10 mM sample 0.08 M NaCl solution and for 20 mM solution 0.16 mM NaCl solution
was used. Final concentration of apoferritin was 5.0 mg/ml and PD-G1-Sp was 3.75
mg/ml.
Two-dimensional SAXS data and integrated one-dimensional curves indicate that sample
with 10 mM salt concentration has crystallinity. Experimental data corresponds to
face-centered cubic (fcc, Fm3m) Bravais lattice with lattice parameter a = 18.2 nm. In
the measured curve SAXS reflections at q = 0.57, 0.68, 0.96 and 1.11 nm-1 correspond
to Miller indices (hkl) = (111), (200), (220) and (311). See figure 24 for two-dimensional
SAXS data, one-dimensional experimental and calculated peak positions and quadratic
Miller indices plotted against the measured qhkl values for calculation of the lattice
parameter.
Also 20 mM sample showed similar behavior as 10 mM sample, but intensities of the
SAXS reflections were lower. This would indicate that 10 mM salt concentration is
more ideal for the crystal formation.
For the 10 mM sample’s structure, q* is 0.34 nm-1 (equation 10). Ratios of the SAXS
reflections divided with q* are
√
3,
√
4,
√
8 and
√
11 indicating a fcc structure. The
lattice parameter a of this structure was determined by plotting the quadratic Miller
indices against the measured qhkl values giving slope m = 29.8843 (equation 11). Slope
multiplied with 2pi gives lattice parameter a = 188 Å = 18.8 nm. Distance d between
two apoferritin centers is 13.3 nm (equation 12). Distance corresponds rather well with
the ferritin diameter of 12 nm.
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Figure 24: One-dimensional SAXS data where curve represents measured data and vertical lines indicate
theoretical reflections of face-centered cubic with lattice parameter a = 18.2 nm (left). Two-dimensional
scattering pattern (right, up). Quadratic Miller indices plotted against the measured qhkl values (right,
down). Line presents linear fit which was used to determine the lattice parameter a.
When SAXS samples were heated to 50 °C, a non-reversible change in structure was
observed. First one of the SAXS reflections was not clearly visible and other ones were
shifted to q = 0.69, 1.00 and 1.15 nm-1. These reflection correspond to same lattice
as before heating, but with lattice parameter a = 17.8 nm and Miller indices (hkl)
= (200), (220) and (311). Shift to higher q indicates a closer packing of the viruses
which would be in line with the DLS results where increase in the temperature lead
to decrease in size of complexes. When sample was cooled back to room temperature,
SAXS reflections remained the same indicating that change is not reversible. In general,
intensity of the reflections decreased upon heating. This might be due to lower amount
of crystallinity.
Similar crystalline arrangement have been observed also previously for solutions of
ferritin and dendrimer. Magnetoferritin and dendrimer with spermine tails have been
studied and formation of face-centered cubic lattice was observed87. Also lattice
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parameter (a = 18.5 nm) and ferritin center distance (d = 13.1 nm) corresponded well
with SAXS results of this study. In addition to ferritin also other protein cages are
known to form fcc lattice structures with dendrimers. For example, CCMV is known
to form these kind of lattices. Differences are seen in the lattice parameter due to the
larger size of CCMV36.
9.4 TEM
Samples without salt, included 100 mg/l apoferritin and 0, 5, 15 or 25 mg/l of PD-G1-Sp
(hereafter sample 1, 2, 3 and 4 respectively). Sample preparation for samples 1 ja 2
were done by adding 2 µl of sample solution on the grid and incubated for 1 minute.
Remaining solution was plotted with filtration paper. For other samples no plotting was
done as no complexes nor did free apoferritin remain on the grid. Instead, solution was
let to dry for one hour so that liquid evaporated. Finally, uranyl acetate was used for
negative staining. In the first samples 0.5% and in the latter ones 2 % uranyl acetate
was used. 2 µl of stain was pipetted on the grid and plotted away without incubation.
Samples with NaCl were prepared from apoferritin and PD-G1-Sp solutions with 10
mM NaCl concentration, and samples were diluted with 10 mM NaCl solution. Final
concentration of apoferritin was 100 mg/l and PD-G1-Sp was 25 mg/l. 3 µl of sample
solution was pipetted on the grid and let incubate for 2 minutes. After incubation rest
of the solution was plotted away. 3 µl of 0.5 % uranyl acetate was used for negative
staining. Staining was done twice, first without incubation and second time with short
incubation.
Samples were prepared on Formward carbon on 400 mesh copper grids (PSI supplies)
or on Carbon film on 300 Hex Mesh copper grids (Electron Microscopy Sciences). Grids
for samples with salt were plasma cleaned before sample preparation.
Samples without salt were prepared to observe how dendrimer concentration affects
complex formation. From DLS data one can conclude that under 10 mg/l dendrimer
concentration no complexes should be formed and only free apoferritin should be seen
in the TEM images. In TEM samples this situation would refer to samples 1 and 2.
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Hypothesis based on DLS measurements may be confirmed when figure 25 of sample
1 and 2 is observed. In TEM images of both samples no complexes is observed and
sample contains only free apoferritin.
Figure 25: An overall TEM image of sample 1 with 100 mg/l apoferritin (left) and sample 2 with 100
mg/l apoferritin and 5 mg/l PD-G1-Sp (right) in water solution.
Also differences between sample 1 and 2 may be distinguished. In closeup image of
sample 1 (figure 26) apoferritin shells may be recognized. In contrary, in TEM pictures
of sample 2 apoferritin shell structure is not clearly seen (figure 26). In both samples
apoferritins are to some extent attached to each others but no clear complexes are
observed. Also particle size in the first one is smaller than in the second one. Calculation
was based on size measurement done with ImageJ-program. Twenty different particles
from each picture was analyzed and average of these measurement gave diameter of 11.9
nm for the first one and 13.1 nm for the second one. Increase in size and disappearance
of apoferritin shells may be due to the dendrimer ferritin interactions leading to coverage
of the ferritin shell with the dendrimer.
In samples 3 and 4, no free apoferritin should be seen but instead complexes should be
detected. As seen from figure 27, no free apoferritin is observed. Instead, complexes
may be identified in image of sample 3. For sample 5 no free ferritin or clear complexes
were observed. Instead, round uniform spheres were noticed. These might be ferritin
clusters covered with the dendrimer. Size of the objects in sample 4 are not in line with
DLS measurements as in DLS size of the complexes in high PD-G1-Sp concentrations
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Figure 26: A closeup TEM image of sample 1 with 100 mg/l apoferritin (left) and sample 2 with 100
mg/l apoferritin and 5 mg/l PD-G1-Sp (right) in water solution.
fluctuated between 2000 and 4000 nm. In these TEM figures objects have a diameter
between 20 and 40 nm. TEM grid of sample 5 seemed damaged, and therefore results
from these images are not as reliable as the others. Besides sample 4, TEM data
supports DLS observations of complex formation.
Figure 27: An overall TEM image of sample 3 with 100 mg/l apoferritin and 15 mg/l PD-G1-Sp (left)
and sample 4 with 100 mg/l apoferritin and 25 mg/l PD-G1-Sp (right) in water solution.
53
In TEM samples with 10 mM salt concentration ordered crystalline arrangement can be
seen as predicted from SAXS results. An overall image of crystallinity and image viewed
possibly from [111] orientation of fcc can be seen from figure 28 and 29 respectively.
Also free apoferritin was observed in the images indicating that dendrimer concentration
is too low or salt concentration too high for total binding.
Figure 28: An overall TEM image of apoferritin and PD-G1-Sp in 10 mM NaCl solution.
Figure 29: An overall (left) and closeup (right, up) TEM image of apoferritin and PD-G1-Sp in 10
mM NaCl solution in 111 orientation. Unit cell presentation along 111 orientation (right, down).
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Also other arrangement could be observed from the images. Figure 30 represents closeup
of different orientations.
Figure 30: TEM images of different orientations.
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9.5 Conclusions
In this Master’s thesis project, we were able to successfully synthesize Newkome-type
spermine dendron with ATRP initiator in the focal point. In situ polymerization of
di(ethylene glycol) methyl ether methacrylate from the dendrimer was also shown to be
achievable. Final product was water soluble and thermoresponsive, as expected, with
cloud point between 25 and 35 °C. Coil-to-globule transition at cloud point was shown
to be reversible.
Final products properties was further studied by complexing it with apoferritin protein
cage. Complexation was based on electrostatic interactions rising from negative charge
of the apoferritin and positive charge of the dendrimer. Complexation did not show clear
dependence on temperature. However, complexes were to some extent thermoresponsive.
Zeta potential of these complexes were shown to be dependent on the dendrimer
concentration, and therefore tunable.
In certain salt solutions apoferritin and the dendrimer had a crystalline structure.
Face-centered cubic structure was observed with lattice parameter a = 18.8 nm. When
these complexes were heated SAXS reflections shifted upwards indicating closer packing
of the viruses. Shift was not reversible.
To improve the final product, synthesis route should be optimized. In this way, longer
polymer tail for the dendron could be achieved. After efficient polymerization is obtained,
cloud point of the polymer could be modified with copolymerization. Longer polymer
tail would probably also improve thermoresponsivness of the complexes. Spermine
dendrons with different generations could be tested to optimize electrostatic binding
between apoferritin and dendrimer. Additionally, different protein cages could be tested.
Advantages of this system lay in the non-covalent assembly of particles and in the
possibility to modify charge and size of the complexes. Thermoresponsiveness of the
complexes should be improved to gain the full potential. Dendrimer and apoferritin
were shown to form crystalline structures which had temperature dependent domain size.
Results of this study may be used in further development of self-assembled materials.
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